Healthcare / Drug Manufacturers - Specialty & GenericTSXV
$0.09
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-991252.00 · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$15M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-282.1%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-24756.5%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11685.0 · net income $-3.5M · FCF $-2.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11685.00 | $11685.00 | — | — | — |
| Net Income | $-3.5M | $-3.5M | $-1.7M | $-1.4M | $-1.8M |
| EBITDA | $-3.5M | $-3.5M | $-1.7M | $-1.4M | $-1.7M |
| EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 |
| Operating Margin | -30231.6% | -30231.6% | — | — | — |
| Net Margin | -30231.6% | -30231.6% | — | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.09 | 0.03 | 0.02 |
| Current Ratio | 0.18 | 0.18 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.9M | $-2.9M | $-302289.00 | $-991252.00 | $-1.7M |
| Returns | |||||
| ROE | -282.1% | -282.1% | -379.4% | -97.5% | -119.8% |
| Valuation | |||||
| P/B | 11.24 | 11.24 | 19.88 | 3.18 | 4.79 |
| Growth & Yield | |||||
| EPS Growth | -100.0% | -100.0% | 0.0% | 50.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-48.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.02
Residual
-48.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.